JP7303107B2 - 自己免疫疾患の診断、予防、および／または治療 - Google Patents

自己免疫疾患の診断、予防、および／または治療 Download PDF

Info

Publication number
JP7303107B2
JP7303107B2 JP2019529463A JP2019529463A JP7303107B2 JP 7303107 B2 JP7303107 B2 JP 7303107B2 JP 2019529463 A JP2019529463 A JP 2019529463A JP 2019529463 A JP2019529463 A JP 2019529463A JP 7303107 B2 JP7303107 B2 JP 7303107B2
Authority
JP
Japan
Prior art keywords
cells
epitope
pla2r
patient
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019529463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524884A5 (enExample
JP2019524884A (ja
Inventor
チュウ，チェンシェン
Original Assignee
イムノワーク，リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イムノワーク，リミテッド ライアビリティ カンパニー filed Critical イムノワーク，リミテッド ライアビリティ カンパニー
Publication of JP2019524884A publication Critical patent/JP2019524884A/ja
Publication of JP2019524884A5 publication Critical patent/JP2019524884A5/ja
Priority to JP2022076451A priority Critical patent/JP7411718B2/ja
Application granted granted Critical
Publication of JP7303107B2 publication Critical patent/JP7303107B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019529463A 2016-08-12 2017-08-11 自己免疫疾患の診断、予防、および／または治療 Active JP7303107B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022076451A JP7411718B2 (ja) 2016-08-12 2022-05-06 自己免疫疾患の診断、予防、および／または治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662374382P 2016-08-12 2016-08-12
US62/374,382 2016-08-12
PCT/US2017/046626 WO2018031947A1 (en) 2016-08-12 2017-08-11 Diagnosis, prevention, and/or treatment of autoimmune diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022076451A Division JP7411718B2 (ja) 2016-08-12 2022-05-06 自己免疫疾患の診断、予防、および／または治療

Publications (3)

Publication Number Publication Date
JP2019524884A JP2019524884A (ja) 2019-09-05
JP2019524884A5 JP2019524884A5 (enExample) 2020-09-03
JP7303107B2 true JP7303107B2 (ja) 2023-07-04

Family

ID=61163324

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019529463A Active JP7303107B2 (ja) 2016-08-12 2017-08-11 自己免疫疾患の診断、予防、および／または治療
JP2022076451A Active JP7411718B2 (ja) 2016-08-12 2022-05-06 自己免疫疾患の診断、予防、および／または治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022076451A Active JP7411718B2 (ja) 2016-08-12 2022-05-06 自己免疫疾患の診断、予防、および／または治療

Country Status (6)

Country Link
US (3) US11266717B2 (enExample)
EP (2) EP3497452B1 (enExample)
JP (2) JP7303107B2 (enExample)
CN (1) CN109891245B (enExample)
ES (1) ES3014985T3 (enExample)
WO (1) WO2018031947A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7303107B2 (ja) * 2016-08-12 2023-07-04 イムノワーク，リミテッド ライアビリティ カンパニー 自己免疫疾患の診断、予防、および／または治療
EP3813885A4 (en) * 2018-05-02 2022-01-12 The Trustees of The University of Pennsylvania Compositions and methods of phospholipase a2 receptor chimeric autoantibody receptor t cells
US12203933B2 (en) 2018-08-15 2025-01-21 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating membranous nephropathy
EP4010704A1 (en) 2019-08-06 2022-06-15 Euroimmun Medizinische Labordiagnostika AG An improved autoantibody detection assay
EP4117702A4 (en) * 2020-03-06 2024-03-13 Mayo Foundation for Medical Education and Research Methods and materials for identifying and treating membranous nephropathy
CN112111015B (zh) * 2020-09-24 2021-12-07 苏州携创生物技术有限公司 PLA2R、C1q、THSD7A融合蛋白及其构建方法、应用
CN112557670A (zh) * 2020-12-07 2021-03-26 东南大学 一种基于尿液外泌体pla2r检测imn的方法、试剂盒及其应用
BR102021022687A2 (pt) 2020-12-11 2022-06-28 Euroimmun Medizinische Labordiagnostika Ag Método e reagentes para diagnosticar nefropatia membranosa
WO2023015239A1 (en) * 2021-08-05 2023-02-09 The Trustees Of The University Of Pennsylvania Compositions and methods of chimeric autoantibody receptor cells expressing extended phospholipase a2 receptor fragments
CN114588881B (zh) * 2022-03-07 2023-07-18 大连理工大学 免疫吸附剂及其制备方法
EP4496815A1 (en) * 2022-03-23 2025-01-29 Bodhi Bio LLC Compositions and methods for antigen-specific therapy
CN116082517B (zh) * 2022-05-26 2025-08-22 成都地奥制药集团有限公司 融合蛋白及其用途
WO2024147113A1 (en) * 2023-01-05 2024-07-11 Glycoera Ag Glycoengineered polypeptides targeting anti-podocyte autoantibodies and uses thereof
CN115951047A (zh) * 2023-02-10 2023-04-11 大连大学 自身免疫性水疱病PBMCs直接免疫荧光诊断试剂盒
WO2024231929A1 (en) * 2023-05-08 2024-11-14 Canopy Immuno-Therapeutics Ltd. Ig-like fusion proteins for treating membranous nephropathy

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009517046A (ja) 2005-11-23 2009-04-30 ジェネンテック・インコーポレーテッド Ｂ細胞アッセイに関する組成物及び方法
JP2011528789A (ja) 2008-07-18 2011-11-24 ボストン メディカル センター コーポレーション 膜性腎症の診断法
US20140255346A1 (en) 2011-05-04 2014-09-11 Cellular Technology, Ltd. Cns antigen-specific b cell, t cell and antibody assays and their uses in diagnosis and treatment of multiple sclerosis
WO2015004603A1 (en) 2013-07-09 2015-01-15 Institut National De La Sante Et De La Recherche Medicale Anti-pla2r antibody and uses thereof
WO2015185949A1 (en) 2014-06-06 2015-12-10 The University Of Manchester Peptides, and methods and apparatus utilising same
CN105510575A (zh) 2015-12-04 2016-04-20 深圳市伯劳特生物制品有限公司 抗磷脂酶A2受体抗体IgG试剂盒及检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0365087B1 (en) 1988-10-21 1992-07-22 Akzo N.V. Immunotoxins for the treatment or prophylaxis of auto-immune diseases
JPH07278196A (ja) * 1994-04-05 1995-10-24 Shionogi & Co Ltd ヒトｉ型ホスホリパーゼａ２レセプター
CA2417885A1 (en) 2000-08-01 2002-02-07 The University Of Kansas Cell internalized peptide-drug conjugates
EP2145684A3 (en) * 2008-07-14 2013-06-26 Samsung Electronics Co., Ltd. Microfluidic device, sample analyzing method using the same, and dilution ration measuring method
WO2012145112A2 (en) 2011-04-18 2012-10-26 Immunogen, Inc. Novel maytansinoid derivatives with sulfoxide linker
JP6208228B2 (ja) 2012-06-21 2017-10-04 ミラゲン セラピューティクス， インコーポレイテッド ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤
CN104849452A (zh) * 2015-05-14 2015-08-19 深圳市伯劳特生物制品有限公司 一种pla2r抗体定量检测试纸条及制作、检测方法
JP7303107B2 (ja) * 2016-08-12 2023-07-04 イムノワーク，リミテッド ライアビリティ カンパニー 自己免疫疾患の診断、予防、および／または治療

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009517046A (ja) 2005-11-23 2009-04-30 ジェネンテック・インコーポレーテッド Ｂ細胞アッセイに関する組成物及び方法
JP2011528789A (ja) 2008-07-18 2011-11-24 ボストン メディカル センター コーポレーション 膜性腎症の診断法
US20140255346A1 (en) 2011-05-04 2014-09-11 Cellular Technology, Ltd. Cns antigen-specific b cell, t cell and antibody assays and their uses in diagnosis and treatment of multiple sclerosis
WO2015004603A1 (en) 2013-07-09 2015-01-15 Institut National De La Sante Et De La Recherche Medicale Anti-pla2r antibody and uses thereof
WO2015185949A1 (en) 2014-06-06 2015-12-10 The University Of Manchester Peptides, and methods and apparatus utilising same
CN105510575A (zh) 2015-12-04 2016-04-20 深圳市伯劳特生物制品有限公司 抗磷脂酶A2受体抗体IgG试剂盒及检测方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ＦＲＥＳＱＵＥＴ Ｍａｒｙｌｉｎｅ ｅｔ ａｌ．， Ｉｄｅｎｔｉｆｉｃａｔｉｏｎ ｏｆ ａ Ｍａｊｏｒ Ｅｐｉｔｏｐｅ Ｒｅｃｏｇｎｉｚｅｄ ｂｙ ＰＬＡ２Ｒ Ａｕｔｏａｎｔｉｂｏｄｉｅｓ ｉｎ Ｐｒｉｍａｒｙ Ｍｅｍｂｒａｎｏｕｓ Ｎｅｐｈｒｏｐａｔｈｙ， ２０１５， Ｊｏｕｒｎａｌ ｏｆ ｔｈｅ Ａｍｅｒｉｃａｎ Ｓｏｃｉｅｔｙ ｏｆ Ｎｅｐｈｒｏｌｏｇｙ， Ｖｏｌ．２６， ｐｐ．３０２－３１３
ＫＡＮＩＧＩＣＨＥＲＬＡ Ｄｕｒｇａ ｅｔ ａｌ．， Ａｎｔｉ－ＰＬＡ２Ｒ ａｎｔｉｂｏｄｉｅｓ ｍｅａｓｕｒｅｄ ｂｙ ＥＬＩＳＡ ｐｒｅｄｉｃｔ ｌｏｎｇ－ｔｅｒｍ ｏｕｔｏｃｏｍｅ ｉｎ ａ ｐｒｅｖａｌｅｎｔ ｐｏｐｕｌａｔｉｏｎ ｏｆ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｉｄｉｏｐａｔｈｉｃ ｍｅｍｂｒａｎｏｕｓ ｎｅｐｈｒｏｐａｔｈｙ， ２０１３， Ｋｉｄｎｅｙ ｉｎｔｅｒｎａｔｉｏｎａｌ， Ｖｏｌ．８３， ｐｐ．９４０－９４８
ＫＡＯ Ｌｉｙｏ ｅｔ ａｌ．， Ｉｄｅｎｔｉｆｉｃａｔｉｏｎ ｏｆ ｔｈｅ Ｉｍｍｕｎｏｄｏｍｉｎａｎｔ Ｅｐｉｔｏｐｅ Ｒｅｇｉｏｎ ｉｎ Ｐｈｏｓｐｈｏｌｉｐａｓｅ Ａ２ Ｒｅｃｅｐｔｏｒ－Ｍｅｄｉａｔｉｎｇ Ａｕｔｏａｎｔｉｂｏｄｙ Ｂｉｎｄｉｎｇ ｉｎ Ｉｄｉｏｐａｔｈｉｃ Ｍｅｍｂｒａｎｏｕｓ Ｎｅｐｈｒｏｐａｔｈｙ， ２０１５， Ｊｏｕｒｎａｌ ｏｆ ｔｈｅ Ａｍｅｒｉｃａｎ Ｓｏｃｉｅｔｙ ｏｆ Ｎｅｐｈｒｏｌｏｇｙ， Ｖｏｌ．２６， ｐｐ．２９１－３０１
ＭＡ Ｈｏｎｇ ｅｔ ａｌ．， Ｔｈｅ Ｒｏｌｅ ｏｆ Ｃｏｍｐｌｅｍｅｎｔ ｉｎ Ｍｅｍｂｒａｎｏｕｓ Ｎｅｐｈｒｏｐａｔｈｙ， ２０１３， Ｓｅｍｉｎａｒ ｉｎ Ｎｅｐｈｒｏｌｏｇｙ， Ｖｏｌ．３３， Ｎｏ．６， ｐｐ．５３１－５４２
ＲＯＮＣＯ Ｐｉｅｒｒｅ， ＤＥＢＩＥＣ Ｈａｎｎａ， Ｐａｔｈｏｐｈｙｓｉｏｌｏｇｉｃａｌ ａｄｖａｎｃｅｓ ｉｎ ｍｅｍｂｒａｎｏｕｓ ｎｅｐｈｒｏｐａｔｈｙ： ｔｉｍｅ ｆｏｒ ａ ｓｈｉｆｔ ｉｎ ｐａｔｉｅｎｔ’ｓ ｃａｒｅ， ２０１５， Ｌａｎｃｅｔ， Ｖｏｌ．３８５，ｐｐ．１９８３－１９９２

Also Published As

Publication number Publication date
EP3497452C0 (en) 2025-03-05
US11266717B2 (en) 2022-03-08
EP3497452A1 (en) 2019-06-19
JP7411718B2 (ja) 2024-01-11
WO2018031947A1 (en) 2018-02-15
EP3497452A4 (en) 2020-01-22
US20190183969A1 (en) 2019-06-20
JP2022097596A (ja) 2022-06-30
CN109891245B (zh) 2023-05-05
EP4644899A2 (en) 2025-11-05
US20220193188A1 (en) 2022-06-23
EP3497452B1 (en) 2025-03-05
ES3014985T3 (en) 2025-04-28
US20240252590A1 (en) 2024-08-01
JP2019524884A (ja) 2019-09-05
CN109891245A (zh) 2019-06-14

Similar Documents

Publication Publication Date Title
JP7411718B2 (ja) 自己免疫疾患の診断、予防、および／または治療
Ji et al. Enhanced natural killer cell immunotherapy by rationally assembling Fc fragments of antibodies onto tumor membranes
KR102581747B1 (ko) 표적 세포 표면 편집을 위한 접합체
EP3154574B1 (en) Homogenous antibody drug conjugates via enzymatic methods
ES2619681T3 (es) Novedosos epítopos P2X7
JP2015516813A5 (enExample)
JP2016531583A (ja) 免疫系調節薬
EP3314258B1 (en) Antigenic peptides and uses thereof for diagnosing and treating autism
AU2014228777B2 (en) BH4 stabilized peptides and uses thereof
AU2016229309B2 (en) Immune system modulators and compositions
EP3097124B1 (en) Means and methods for detecting activated malt1
Tang et al. Presentation of epitopes on genetically engineered peptides and selection of lymphoma-targeting moieties based on epitope biorecognition
JP2008537096A (ja) Ｃｘｃｒ３はグリアジンレセプターである
JPWO2006025525A1 (ja) 樹状細胞において抗原提示されやすいタンパク質の選択方法
WO2024123896A2 (en) Targeting sortilin
CN118613492A (zh) Tfpi结合多肽及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211006

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220506

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220506

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220531

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220620

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220621

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220708

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220712

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221101

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20221206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230622

R150 Certificate of patent or registration of utility model

Ref document number: 7303107

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150